Literature DB >> 17046240

Evidence-based treatment of metastatic breast cancer - 2006 recommendations by the AGO Breast Commission.

Gunter von Minckwitz1.   

Abstract

The Breast Commission of the German Gynecological Oncology Working Group AGO revises in annual intervals their evidence-based recommendations on therapy of primary and advanced breast cancer. A purely scientific assessment of the most recent published literature according to standardized level of evidence and grade of recommendation is supplemented by a newly developed AGO recommendation system which constitutes an expert consensus considering also clinical relevance, feasibility, and compliance. It is an approach of providing readers with an additional assessment trying to help them to select the most appropriate treatment for the individual patient situation. In the following, an overview is given on the most important aspects in diagnosis and therapy of metastatic breast cancer. For detailed aspects, a comprehensive set of slides including a more complete bibliography may be accessed under .

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046240     DOI: 10.1016/j.ejca.2006.06.033

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

1.  Adherence to Treatment Guidelines in Breast Cancer Care - a Retrospective Analysis of the 'Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie'

Authors:  Christian Jackisch; Michael Untch; Dimitrios Chatsiproios; Christiane Lamparter; Friedrich Overkamp; Werner Lichtenegger; Wolfgang Rönsberg; Christoph Thomssen; Gunter von Minckwitz; Ute-Susann Albert
Journal:  Breast Care (Basel)       Date:  2008-04-25       Impact factor: 2.860

2.  Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial.

Authors:  Lawrence G Lum; Archana Thakur; Zaid Al-Kadhimi; Gerald A Colvin; Francis J Cummings; Robert D Legare; Don S Dizon; Nicola Kouttab; Abby Maizel; William Colaiace; Qin Liu; Ritesh Rathore
Journal:  Clin Cancer Res       Date:  2015-02-16       Impact factor: 12.531

3.  DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment.

Authors:  Fernanda Faião-Flores; José Agustín Quincoces Suarez; Paulo Celso Pardi; Durvanei Augusto Maria
Journal:  Tumour Biol       Date:  2011-12-23

4.  A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.

Authors:  Juan Bayo; María Lomas; Javier Salvador; Alberto Moreno; Manuel Ruiz; Alberto Rodríguez; José Fuentes; Ana Fernández-Freire; Reyes Bernabé; Andrea Fernández
Journal:  Clin Transl Oncol       Date:  2008-12       Impact factor: 3.405

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.